LifeSciences BC > News > Member Announcements

Print Friendly

Aquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2017 Annual Bloom Burton & Co. Healthcare Investor … Continue reading Aquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference

DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme

April 25, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., April 25, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has entered into a three-year collaboration with Duke University to evaluate VAL-083, the Company’s platform compound, as … Continue reading DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme

Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference

April 24, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, BC. April 24, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the sixth annual Bloom Burton & Co. Healthcare Investor Conference … Continue reading Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference

Arbutus Announces ARB-1467 Data Presentation at EASL

April 24, 2017
Arbutus Biopharma Corporation

ARB-1467 Reduces Serum HBsAg in Both HBeAg Negative and HBeAg Positive PatientsResults of Biweekly Dosing from Cohort 4 Expected in 3Q17Additional Study Starting in 2H17 to Evaluate Longer Term Dosing with Immune Modulatory Agents VANCOUVER, British Columbia and WARMINSTER, Pa., April 22, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus … Continue reading Arbutus Announces ARB-1467 Data Presentation at EASL

DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants

April 24, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., April 21, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has closed its previously announced registered public offering of an aggregate of 2,769,232 shares of common stock … Continue reading DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants

High Response and Remission Rates in Anti-TNFa Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease

April 24, 2017
Qu Biologics Inc.

Vancouver, British Columbia – April 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high response and remission rates in anti-TNFα naïve patients in its recently completed randomized, placebo controlled trial in moderate to severe Crohn’s … Continue reading High Response and Remission Rates in Anti-TNFa Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease

Serial 14-3-3? testing: informing RA flare and joint damage risk as you treat-to-target

April 19, 2017
AUGUREX LIFE SCIENCES CORP.

Vancouver, BC – April 19, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and Japan will present data on 14-3-3η blood testing in Rheumatoid Arthritis (RA). “Studies to be presented at JCR … Continue reading Serial 14-3-3? testing: informing RA flare and joint damage risk as you treat-to-target

Quark Venture and GFSecurities is pleased to announce a $US 5 million investment to advance Lyndra’s Ultra-Long Acting Oral Therapeutic Delivery Platform

April 19, 2017
Quark Venture

The company’s platform has the potential to transform patient care by improving therapeutic efficacy, reducing side effects, and generating cost-savings to patients and healthcare systems. “This is yet another breakthrough technology conceived in the Massachusetts Institute of Technology (MIT) lab of Dr. Robert Langer, and our second investment. Patients are looking for better solutions and … Continue reading Quark Venture and GFSecurities is pleased to announce a $US 5 million investment to advance Lyndra’s Ultra-Long Acting Oral Therapeutic Delivery Platform

DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants

April 13, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., April 13, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has priced a registered public offering of an aggregate of 2,769,232 shares of common stock and warrants … Continue reading DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants